仁和药业公告，拟调整"女性生理健康用品生产线数字智能化技改搬迁及扩产项目"投资规模并予以结 项，终止"数字化保健和消毒抑菌产品生产线技改搬迁及扩产项目"，并将相关募集资金永久补充流动资 金。 ...

国泰海通证券股份有限公司 关于仁和药业股份有限公司 调整部分募投项目投资规模并结项、终止部分项目并将相 关募集资金永久补充流动资金的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 仁和药业股份有限公司（以下简称"仁和药业"或"公司"）2020 年向特定对象 发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易 所股票上市规则》《上市公司募集资金监管规则》和《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等相关规定，对公司调整部分 募投项目投资规模并结项、终止部分项目并将相关募集资金永久补充流动资金事 项进行了核查，具体情况如下： 单位：万元 | 项目名称 | 募集资金拟投资 | 累计已投入募集 | 结余募集资金 | | --- | --- | --- | --- | | | 总额 | 资金总额 | 金额 | | 数字化保健和消毒抑菌产品生 产线技改搬迁及扩产项目 | 7,962.00 | 6,596.59 | 1,365.41 | | 女性生理健康用品生产线数字 智能化技改搬迁及扩产项目 | 7,963.26 | 5,309.95 | ...

相关募集资金永久补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：000650 证券简称：仁和药业 公告编号：2025-045 仁和药业股份有限公司 关于调整部分募投项目投资规模并结项、终止部分项目并将 | 序号 | 项目名称 | 募集资金承诺投资总 额 | 调整后投资总额 | | --- | --- | --- | --- | | 1 | 仁和翔鹤工业大麻综合利用产业项目 | 27,910.65 | 2,496.58 | | 2 | 中药经典名方产业升级技改项目 | 18,855.00 | 12,428.60 | | 3 | 仁和智慧医药物流园项目 | 22,974.00 | 22,974.00 | | 4 | 仁和研发中心建设项目 | 13,645.00 | 4,146.14 | | 5 | 数字化保健和消毒抑菌产品生产线技 改搬迁及扩产项目 | - | 7,962.00 | | 6 | 女性生理健康用品生产线数字智能化 技改搬迁及扩产项目 | - | 7,963.26 | | 7 | 永久补充流动资金 | - | 25,414 ...

证券代码：000650 证券简称：仁和药业 公告编号：2025-046 仁和药业股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 6、会议的股权登记日：2025 年 12 月 19 日 7、出席对象： （1）截至 2025 年 12 月 19 日下午 15:00 收市，在中国证券登记结算有限责任公司深圳分公司登记 在册的本公司全体股东；不能出席现场会议的股东，可以书面形式委托代理人出席会议和参加表决，该 代理人不必是本公司股东； （2）公司董事和高级管理人员； （3）公司聘请的律师。 8、会议地点：江西省樟树市仁和路 36 号公司会议室 二、会议审议事项 1、本次股东会提案编码表 4、会 ...

二、董事会会议审议情况 经与会董事认真审议，会议审议通过了如下议案。 证券代码：000650 证券简称：仁和药业 公告编号：2025-044 仁和药业股份有限公司 第十届董事会第五次会议决议公告 本公司及全体董事会成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 仁和药业股份有限公司（以下简称"公司"）第十届董事会第五次会议通知 于 2025 年 12 月 5 日以直接送达、电子邮件等方式发出，会议于 2025 年 12 月 9 日以现场与通讯结合方式在南昌元创国际 18 层公司会议室召开。会议应到董事 9 人，实到董事 9 人。董事长杨潇先生主持本次会议，公司高管列席会议，会议 符合《中华人民共和国公司法》和《公司章程》的有关规定。 1、审议通过了《关于调整部分募投项目投资规模并结项、终止部分项目并 将相关募集资金永久补充流动资金的议案》。 具体内容详见巨潮资讯网（http://www.cninfo.com.cn）刊登的《关于调整 部分募投项目投资规模并结项、终止部分项目并将相关募集资金永久补充流动资 金的公告》。 本议案已经董事会审计委员会审议通过； ...

（文章来源：证券日报） 证券日报网讯 12月3日，仁和药业在互动平台回答投资者提问时表示，公司目前正努力推动ULOOK眼 镜尽快正式上市销售。 ...

格隆汇12月3日丨仁和药业(000650.SZ)在投资者互动平台表示，公司目前正努力推动ULOOK眼镜尽快 正式上市销售。 ...

Group 1 - The company, Renhe Pharmaceutical, has prioritized the supply of key medications such as Oseltamivir Phosphate, Ibuprofen, and Compound Paracetamol and Amantadine Capsules in response to high market demand [1]

Core Viewpoint - The company, Renhe Pharmaceutical, confirmed the availability of several influenza treatment medications and emphasized its commitment to ensuring stable production and supply to meet market demand [2]. Product Information - The company currently sells influenza treatment medications including Oseltamivir Phosphate Capsules, Ibuprofen Sustained-Release Capsules, Amoxicillin Capsules, Compound Aminophenol and Amantadine Capsules, Strong Loquat Capsules, and Pediatric Acetaminophen Granules [2]. - In addition to these, the company offers various medications for symptoms related to influenza-like illnesses, providing consumers with multiple options for symptomatic relief [2]. Supply Assurance - The company has prioritized the supply of these influenza-related medications to ensure they meet market demand effectively [2].

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]